Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SHSE:688580'
s EV-to-FCF Range Over the Past 10 Years
Min: -2027.51 Med: 57.44 Max: 4142.21
Current: 625.01
During the past 13 years, the highest EV-to-FCF of Nanjing Vishee Medical Technology Co was 4142.21. The lowest was -2027.51. And the median was 57.44.
SHSE:688580's EV-to-FCF is ranked worse than 97.58% of 414
companies
in the Medical Devices & Instruments industry
Industry Median: 23.16
vs SHSE:688580: 625.01
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Nanjing Vishee Medical Technology Co (SHSE:688580) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Nanjing Vishee Medical Technology Co's PE Ratio (TTM) for today is calculated as:
Nanjing Vishee Medical Technology Co's share price for today is ¥50.56.
Nanjing Vishee Medical Technology Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥1.730.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Nanjing Vishee Medical Technology Co EV-to-FCF Related Terms
Nanjing Vishee Medical Technology Co EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nanjing Vishee Medical Technology Co EV-to-FCF Chart
SHSE:688580 vs ABT, SYK, MDT: EV-to-FCF Comparison
For the Medical Devices subindustry, Nanjing Vishee Medical Technology Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nanjing Vishee Medical Technology Co EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Nanjing Vishee Medical Technology Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Nanjing Vishee Medical Technology Co's EV-to-FCF falls into.
Nanjing Vishee Medical Technology Co's current Enterprise Value is ¥3,911.3 Mil.
Nanjing Vishee Medical Technology Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥6.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nanjing Vishee Medical Technology Co (SHSE:688580) has a EV-to-FCF of 625.01 as of Jul. 19, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Nanjing Vishee Medical Technology Co and its competitors. This is 988% above median its historical median of 57.44. According to the industry distribution chart, Nanjing Vishee Medical Technology Co ranks #404 out of 414 companies in the Medical Devices & Instruments industry, placing it in the top 97.6%.
Is Nanjing Vishee Medical Technology Co's EV-to-FCF too high?
Nanjing Vishee Medical Technology Co's current EV-to-FCF of 625.01 is 988% above median its 10-year median of 57.44. The Medical Devices & Instruments industry median EV-to-FCF is 23.16. Nanjing Vishee Medical Technology Co's value of 625.01 is 2598.7% above this industry median. Based on the distribution chart, Nanjing Vishee Medical Technology Co ranks #404 out of 414 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Nanjing Vishee Medical Technology Co has a GF Score™ of 89/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Nanjing Vishee Medical Technology Co's EV-to-FCF compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Nanjing Vishee Medical Technology Co ranks #404 out of 414 companies for EV-to-FCF. This places Nanjing Vishee Medical Technology Co in the lower half of its industry. The industry median EV-to-FCF is 23.16. Nanjing Vishee Medical Technology Co's value of 625.01 is 2598.7% above this benchmark. While the company's 10-year median is 57.44 vs. the industry median of 23.16, Nanjing Vishee Medical Technology Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 23.16, based on 414 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nanjing Vishee Medical Technology Co's current EV-to-FCF of 625.01 is 2598.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Nanjing Vishee Medical Technology Co and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 23.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nanjing Vishee Medical Technology Co's current EV-to-FCF is 625.01, which is 988% above median its own 10-year median of 57.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanjing Vishee Medical Technology Co stock overvalued right now?
Based on GuruFocus' analysis, Nanjing Vishee Medical Technology Co (SHSE:688580) is currently considered Fairly Valued. The stock's GF Value™ is ¥54.15, compared to a current price of ¥50.56 — trading 6.6% below its estimated fair value. The current EV-to-FCF is 625.01, which is 988% above median its 10-year median of 57.44 and 2598.7% above the Medical Devices & Instruments industry median of 23.16. Nanjing Vishee Medical Technology Co's overall GF Score™ is 89/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Nanjing Vishee Medical Technology Co (SHSE:688580), the current EV-to-FCF is 625.01 as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nanjing Vishee Medical Technology Co (SHSE:688580) Overvalued in 2026?
Based on GuruFocus' analysis, Nanjing Vishee Medical Technology Co stock appears to be undervalued.
The current stock price of ¥50.56 is trading 6.6% below its estimated GF Value™ of ¥54.15.
GuruFocus considers Nanjing Vishee Medical Technology Co to be Fairly Valued.
Key valuation signals for SHSE:688580:
EV-to-FCF: 625.01 (988% above median its 10-year median of 57.44)
GF Value™: ¥54.15 vs. price of ¥50.56 (6.6% below fair value)
Industry Position: 2598.7% above the Medical Devices & Instruments median (#404 of 414)
No single metric tells the full story. See the SHSE:688580 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nanjing Vishee Medical Technology Co Business Description
Nanjing Vishee Medical Technology Co Ltd is engaged in production and sales of rehabilitation medical devices. The company's products under Pelvic floor and postpartum rehabilitation include Pelvic floor electromyography biofeedback instrument; Myotrac series biological stimulation feedback instrument; Ruiyi Series Biostimulation Feedback Apparatus; Magneuro Series Magnetic Stimulator; Female psychological rehabilitation; Neonatal electroencephalograph; Consumables; and under Mental rehabilitation include Multi-parameter biofeedback instrument; Group biofeedback; Magneuro Series Magnetic Stimulator; and Cognitive dysfunction treatment software.
89GF Score
Get the complete analysis for SHSE:688580
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688580 has been successfully added to your 
